Patent · US Active

Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation

US12370158B2 · kind B2 · utility

0Cited by

0References

5Claims

0Family size

Assignees

OMEICOS Therapeutics GmbH · DE
Max Delbrück-Centrum Für Molekulare Medizin · DE

Inventors

Robert Fischer · Berlin, DE
Wolf-Hagen Schunck · Berlin, DE
Dominik Müller · Berlin, DE
Tim Wesser · Berlin, DE
Anne Konkel · Berlin, DE
Janine Lossie · Berlin, DE

Key dates

Filing date	Jul 22, 2021
Grant date	Jul 29, 2025
Priority date	—
Expiry date	Oct 23, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P29/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs) for use in treating or reducing the risk of developing or preventing: (i) neovascularization and/or (ii) inflammatory disorder, in particular, ophthalmic disorders associated with neovascularization and/or inflammation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.